Clinical trial · Observational
Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
Zhongnan Hospital of Wuhan University
NCT04688606CI-TRIAL-00049186unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through the screening of CTCs in patients with suspected liver cancer and liver tumor resection or liver transplantation, the number of CTCs in the blood of liver cancer patients before and after surgery is monitored, and the clinical application significance of CTCs in liver cancer screening and postoperative recurrence monitoring in liver cancer patients is evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating tumor cell capture technology | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Two groups
- description
- 1. Initial diagnosis of suspected hepatocellular carcinoma; 2. patients undergoing liver transplantation, radical resection or ablation of liver cancer
- interventionNames
- Diagnostic Test: Circulating tumor cell capture technology
Primary outcomes (1)
- measure
- Clinical detection of circulating tumor cells
- timeFrame
- 2020.01.20-2021.02.28
- description
- To evaluate the specificity of CTCs for liver cancer screening and the feasibility of early recurrence after interventional therapy, tumor resection or liver transplantation
Secondary outcomes (1)
- measure
- Circulating tumor cell function detection and verification
- timeFrame
- 2020.03.01-2021.05.20
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Primary diagnosis of suspected hepatocellular carcinoma; or liver cancer patients who have undergone liver transplantation, radical resection or ablation of liver cancer; 2. Age 18-75 years old; 3. ASA (risk of anesthesia) score I-II; 4. The ECOG score is 0-1; Exclusion Criteria: 1. In addition to hepatocellular carcinoma, patients diagnosed with other types of tumors; 2. Patients with extrahepatic or lymphatic metastasis; 3. Patients who still have serious complications 4 weeks after surgery; 4. Patients who cannot provide informed consent;
References
Publications (0)
Data not yet available
No reference posted for this study.